Allan Jonathan's Form 4 filing
Stoke Therapeutics, Inc.STOK · filed Aug 20, 2025
- Accession no.
- 0001415889-25-022440
- Filed
- Aug 20, 2025
- Trade date
- Aug 18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $30.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Allan JonathanCIK 0001966716 | Officer (GENERAL COUNSEL & CORP SEC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | SSaleDisposed | −1,683 | $18.24F2 | −$30,697.92 | 23,948 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.
Referenced by the price of 1 transaction in Table I.